Mirtazapine is the optimal single agent for this clinical presentation
For a 20-year-old female with severe depression, insomnia, and poor appetite, mirtazapine (Remeron) starting at 7.5-15 mg at bedtime is the most appropriate first-line antidepressant. This medication uniquely addresses all three target symptoms simultaneously through its pharmacologic profile 1.
Rationale for Mirtazapine Selection
Mirtazapine stands out among antidepressants because it:
- Promotes sleep through sedating properties (dose at bedtime) 1
- Stimulates appetite and weight gain as a characteristic side effect 1
- Treats severe depression with efficacy comparable to other second-generation antidepressants 2
- Has a faster onset of action than SSRIs like fluoxetine, paroxetine, or sertraline 2
The guideline evidence explicitly states mirtazapine is "potent and well tolerated; promotes sleep, appetite, and weight gain" with dosing from 7.5 mg at bedtime up to 30 mg at bedtime 1. This side effect profile, typically undesirable in other contexts, becomes therapeutically advantageous for this specific patient presentation.
Dosing Strategy
Start with 7.5-15 mg at bedtime 1. The lower dose (7.5 mg) is often more sedating due to predominant antihistamine effects, while higher doses (15-30 mg) provide stronger noradrenergic effects. For this patient prioritizing sleep and appetite, beginning at 7.5-15 mg is appropriate, with titration to 30 mg maximum based on antidepressant response over 4-8 weeks 1.
Alternative Approaches if Mirtazapine Fails or Is Not Tolerated
If mirtazapine proves ineffective or causes intolerable side effects (excessive sedation, weight gain beyond therapeutic benefit):
Second-line option: Switch to an SSRI (sertraline 25-50 mg daily or escitalopram 10 mg daily) 1, 2 plus a short-term benzodiazepine receptor agonist for insomnia:
This combination approach is supported by clinical experience showing safety and efficacy when targeting multiple sleep-wake mechanisms 3. However, note that SSRIs alone may worsen insomnia initially 4, 5, necessitating the hypnotic co-prescription.
Third-line option: Trazodone 50 mg at bedtime (sedating antidepressant with moderate evidence for sleep improvement) 3 combined with a full-dose SSRI/SNRI for depression. Trazodone has minimal anticholinergic effects compared to older tricyclics 3 but requires full antidepressant dosing of the primary agent since low-dose trazodone alone is insufficient for major depression 3.
Critical Caveats
Monitor for suicidality closely in this young adult, particularly in the first 4-8 weeks. While no single antidepressant shows higher suicide risk than others 2, SSRIs are associated with increased nonfatal suicide attempts 2. Mirtazapine may be preferable in patients with suicidal ideation 6.
Avoid activating antidepressants (bupropion, fluoxetine, venlafaxine) 1 as first-line agents since they can exacerbate insomnia and require co-prescription of hypnotics.
Benzodiazepines for insomnia should be short-term only (not chronic use) in this young patient due to tolerance, dependence, and cognitive impairment risks 1, 3. The non-benzodiazepine hypnotics (Z-drugs) have lower but not absent abuse potential.
Reassess at 4-8 weeks for therapeutic response. Full antidepressant trials require this duration 1. If partial response occurs, consider augmentation with aripiprazole rather than switching 6.
Avoid antihistamines, herbal supplements, and OTC sleep aids as they lack efficacy data and carry anticholinergic risks 3.
What Not to Do
Do not prescribe tricyclic antidepressants (amitriptyline, doxepin) as first-line despite their sedating properties—they carry significant anticholinergic burden, cardiotoxicity risk, and lethality in overdose 1, making them inappropriate for a young patient with severe depression.
Do not use antipsychotics (quetiapine, olanzapine) for insomnia alone given insufficient evidence, significant metabolic side effects, and weight gain risks that exceed therapeutic benefit 3.